Can-Fite BioPharma Ltd. (CANF)

NYSEAMERICAN: CANF · IEX Real-Time Price · USD
4.12
-0.04 (-0.96%)
Feb 2, 2023, 10:06 AM EST - Market open
-0.96%
Market Cap 13.23M
Revenue (ttm) 252,890
Net Income (ttm) -3.55M
Shares Out 3.18M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,214
Open 4.16
Previous Close 4.16
Day's Range 4.08 - 4.17
52-Week Range 3.78 - 12.90
Beta 1.01
Analysts n/a
Price Target n/a
Earnings Date Mar 23, 2023

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Employees 8
Stock Exchange NYSEAMERICAN
Ticker Symbol CANF
Full Company Profile

Financial Performance

In 2021, CANF's revenue was 853,000, an increase of 11.80% compared to the previous year's 763,000. Losses were -12.62 million, -12.66% less than in 2020.

Financial numbers in ILS Financial Statements

News

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

1 week ago - Business Wire

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

3 weeks ago - Business Wire

Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

3 weeks ago - Business Wire

Can-Fite Announces ADS Ratio Change

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

1 month ago - Business Wire

Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

1 month ago - Business Wire

Can-Fite's Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets' Osteoarthritis

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

2 months ago - Business Wire

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla...

2 months ago - Business Wire

Can-Fite: Positive New Data from it's Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd.

3 months ago - Business Wire

Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd.

4 months ago - Business Wire

Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

5 months ago - Business Wire

Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

5 months ago - Business Wire

Can-Fite's Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory,...

5 months ago - Business Wire

Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

5 months ago - Business Wire

Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

6 months ago - Business Wire

All You Need to Know About CanFite Biopharma Ltd (CANF) Rating Upgrade to Buy

CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

7 months ago - Business Wire

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that ...

7 months ago - Benzinga

Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

7 months ago - Business Wire

Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

8 months ago - Business Wire

Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

9 months ago - Business Wire

Can-Fite Granted Key NASH Patent in Israel

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

9 months ago - Business Wire

Can-Fite's CEO to Present Namodenoson's Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...

9 months ago - Business Wire

Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model

10 months ago - Business Wire

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

11 months ago - Business Wire